Related Experiment Videos
Tamoxifen prevents bone loss in ovariectomized mice
13rd Clinic of Internal Medicine, Faculty of Medicine, Charles University, Praha, Czechoslovakia.
Endocrine Regulations
|December 1, 1991
Summary
Tamoxifen treatment prevented bone density loss and maintained uterus weight in ovariectomized mice, demonstrating estrogen-like effects. This study highlights tamoxifen
Area of Science:
- Endocrinology
- Pharmacology
- Bone Biology
Background:
- Ovariectomy in mice leads to decreased bone density and mineral content.
- Estrogen deficiency is a primary cause of bone loss post-menopause.
- Tamoxifen is a selective estrogen receptor modulator with potential bone-protective effects.
Purpose of the Study:
- To investigate the effects of tamoxifen on bone density and mineral content in ovariectomized mice.
- To assess the estrogen-like action of tamoxifen on bone and uterine tissue.
Main Methods:
- Ovariectomy was performed on mice to induce estrogen deficiency.
- Tamoxifen was administered to a group of ovariectomized mice.
- Bone density, calcium, and phosphate content of femora were measured.
- Uterus weight was compared between groups.
Main Results:
- Ovariectomized mice showed significantly decreased bone density and mineral content in femora.
- Tamoxifen-treated ovariectomized mice did not exhibit a decrease in bone density or mineral content.
- Uterus weight in tamoxifen-treated ovariectomized mice was similar to intact controls.
Conclusions:
- Tamoxifen administration in vivo effectively prevented bone mineral loss in ovariectomized mice.
- Tamoxifen demonstrated estrogen-like effects by preserving bone density and uterus weight.
- These findings support tamoxifen's potential as a therapeutic agent for estrogen deficiency-related bone loss.